Answers are grounded in this paper and cite their sources.
Assessment confirms reliability of a commercial anti-PXDN antibody for immunofluorescence in kidney tissues, suggesting effective detection of PXDN expression and localization.
Abstract Peroxidasin (PXDN) is a multidomain heme peroxidase that catalyzes sulfilimine crosslinks in type IV collagen, a reaction essential for basement membrane stability. In addition to its structural role, PXDN has been implicated in oxidative stress regulation, fibrosis, and tumorigenesis. Antibody-based detection is critical for defining PXDN expression and localization, yet few commercial reagents have been rigorously validated, limiting reproducibility. Here, we assessed the specificity and performance of a commercially available anti-PXDN antibody (Abbexa, abx101906) in immunofluorescence applications. Validation was performed in formalin-fixed, paraffin-embedded human kidney tissue and a primary kidney fibroblast line under PXDN silencing and overexpression conditions. The antibody yielded reproducible labeling patterns and demonstrated specificity across cellular contexts. These findings establish abx101906 as a reliable tool for immunofluorescence-based detection of PXDN. This validation provides a foundation for future studies of PXDN biology in kidney development, disease, and potential therapeutic targeting.
No takes yet. Share an insight, caveat, or question.
Brandão et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: